UPC
NASDAQ · Pharmaceuticals
Universe Pharmaceuticals Inc
$2.80
-0.20 (-6.66%)
Financial Highlights (FY 2026)
Revenue
23.64M
Net Income
-4,861,694
Gross Margin
35.3%
Profit Margin
-20.6%
Rev Growth
-28.1%
D/E Ratio
0.16
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 35.3% | 35.3% | 38.4% | 38.4% |
| Operating Margin | -19.0% | -17.1% | 14.7% | 13.8% |
| Profit Margin | -20.6% | -19.5% | 13.5% | 15.5% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 23.64M | 32.87M | 677.4K | 654.6K |
| Gross Profit | 8.34M | 11.60M | 259.9K | 251.1K |
| Operating Income | -4,497,138 | -5,626,893 | 99.6K | 90.3K |
| Net Income | -4,861,694 | -6,083,031 | 91.7K | 101.2K |
| Gross Margin | 35.3% | 35.3% | 38.4% | 38.4% |
| Operating Margin | -19.0% | -17.1% | 14.7% | 13.8% |
| Profit Margin | -20.6% | -19.5% | 13.5% | 15.5% |
| Rev Growth | -28.1% | -28.1% | +6.4% | -8.3% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 119.6K | 119.6K | 155.8K | 159.5K |
| Total Equity | 725.4K | 725.4K | 1.13M | 1.17M |
| D/E Ratio | 0.16 | 0.16 | 0.14 | 0.14 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -4,082,988 | -5,392,518 | 139.8K | 143.9K |
| Free Cash Flow | — | — | 93.2K | 84.6K |